Takeda acid-suppressing drug Walker China is listed.

Reflux esophagitis is a common disease of the digestive system, its characteristic symptoms include heart burn and acid caused by reflux of stomach contents, can be accompanied by symptoms outside the esophagus, and the presence of esophagus mucosa erosion, seriously affecting the patient's life and sleep quality.
epidemiological data show that the prevalence of reflux esophagitis in the general population in China as a new generation of acid suppression drugs, clinical data show that Walker ® has the first dose of full efficacy, persistent acid suppression and convenient to take and so on.
Walker ® marketed in China, will provide new options for clinical use of RE therapy.
Vunorialic tablets, which were launched in Japan in February 2015, include reflux esophagitis, stomach ulcers, duodenal ulcers, prevention of recurrence of stomach ulcers or duodenum ulcers and the eradication of Helicobacter pylori during treatment with low-dose aspirin or nonsteroidal anti-inflammatory drugs.
.